ADAR1 Capital Management, LLC
10% 持股人 Owner
ADAR1 Capital Management, LLC is a Texas-based investment adviser and hedge fund manager organized as a Texas limited liability company, with its principal place of business in Austin, Texas.[[1]](https://www.caplight.com/investor/adarone)[[3]](https://radientanalytics.com/firm/adv/adar1-capital-management-llc-299694) Founded in 2019, the firm serves as a discretionary investment adviser to private, pooled investment vehicles, managing a therapeutics-focused hedge fund strategy and reporting a multi-hundred-million to billion-dollar U.S. equity portfolio through its Form 13F filings.[[1]](https://www.caplight.com/investor/adarone)[[4]](https://hedgefollow.com/funds/ADAR1+Capital+Management+LLC)[[8]](https://www.holdingschannel.com/13f/adar1-capital-management-llc-top-holdings/) As of late 2025–early 2026, ADAR1 Capital Management, LLC reported 13F portfolio values in the range of approximately $1.7 billion, reflecting a diversified set of long U.S. equity holdings across the biopharmaceutical and healthcare sectors.[[6]](https://fintel.io/i/adar1-capital-management-llc)[[8]](https://www.holdingschannel.com/13f/adar1-capital-management-llc-top-holdings/)
The firm operates as a registered investment adviser, filing Form ADV with the SEC under firm number 299694, and is led by Founder and Chief Investment Officer Daniel Schneeberger, MD, MBA, who established ADAR1 Capital Management in January 2019.[[3]](https://radientanalytics.com/firm/adv/adar1-capital-management-llc-299694)[[7]](https://adviserinfo.sec.gov/firm/summary/299694)[[2]](https://www.linkedin.com/in/daniel-schneeberger-a742a751) Schneeberger’s background includes prior work as a consultant at McKinsey & Company advising pharmaceutical and private equity clients on R&D and portfolio strategy, as well as clinical training in internal medicine, emergency medicine, and intensive care in Switzerland.[[2]](https://www.linkedin.com/in/daniel-schneeberger-a742a751) He holds a medical diploma and doctorate in rheumatology from the University of Basel, where he graduated with top honors, and an MBA from Harvard Business School, where he was named a Baker Scholar.[[2]](https://www.linkedin.com/in/daniel-schneeberger-a742a751) In its role as a corporate insider and 10% owner in issuers such as Rallybio Corp (RLYB), ADAR1 Capital Management, LLC exercises significant shareholder influence consistent with its focus on therapeutics and life sciences investments.[[1]](https://www.caplight.com/investor/adarone)[[6]](https://fintel.io/i/adar1-capital-management-llc)
查看完整内部人档案 →